Catalent acquires ERYTECH's U.S. manufacturing facility for $44.5M

Catalent has acquired ERYTECH's U.S. cell therapy manufacturing facility for $44.5 million. The companies also entered a long-term supply agreement for eryaspase (GRASPA).

“Catalent acquired ERYTECH’s U.S. cell therapy manufacturing facility for a total consideration of USD 44.5 million.”stocktitan.net

• 1 source
• stocktitan.netERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent | ERPY Stock NewsStock TitanApr 25, 2022

Summarized from public sources; check the original articles before acting on it.